Insulet (PODD) Akcija Цена
Insulet Цена
Prihod je rastao 41,6 % godišnje u poslednjih 19 godina na 2,71 Млрд USD. Zarada po akciji rasla je 81,5 % godišnje u poslednjih 7 godina. neto marža kompanije Insulet sada iznosi 9,1 %, porasla sa 1,5 % pre nekoliko godina. Medijana analitičke ciljane cene je 180,00 USD, odnosno iznad trenutnu cenu za 20,1 %. Od 32 analitičara 19 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Insulet
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Insulet poslovni model i analiza akcije
Često postavljana pitanja o akciji Insulet
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 185,18 USD za akciju Insulet (medijana: 180,00 USD), što znači +25,5 % u odnosu na poslednju cenu. Konsenzus se zasniva na 32 ocena.
32 analitičara trenutno ocenjuje akciju Insulet: 19 preporučuje kupovinu, 13 držanje i 0 prodaju. Za 2026 analitičari očekuju da Insulet ostvari prihod 3,29 Млрд USD i zaradu po akciji 6,62 USD.
Po trenutnom kursu akcija Insulet kotira 134,46 EUR (149,83 USD).
Akcija Insulet (PODD) kotira na 5 berze, uključujući: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
očekivana prihod od Insulet je 3,29 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Insulet je 467,79 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Insulet je trenutno 22,63. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Insulet.
Odnos cene i prihoda (KUV) za Insulet je trenutno 3,22. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Insulet.
Eulpool score kvaliteta za Insulet je 6/10.
ISIN za Insulet je US45784P1012. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Insulet je A0MQX8. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Insulet je PODD. Simbol tikera se koristi za trgovinu akcijama Insulet na berzanskom tržištu.
Insulet акција
Insulet Peer grupa
Insulet Тикер
Insulet FIGI
Sve ključne metrke i detaljne analize Insulet u dubinskoj analizi
Naša analiza akcija za akciju Insulet uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Insulet. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: